OBJECTIVE：To systematically review the efficacy and safety of different doses of canagliflozin in the treatment of type 2 diabetes，and provide evidence-based reference for the clinical treatment. METHODS：Retrieved from PubMed，Cochrane Library，Clinical Trails.gov，CJFD，Wangfang Database and VIP，randomized controlled trials （RCT） about different doses of canagliflozin in the treatment of type 2 diabetes were collected. Meta-analysis was performed by using Rev Man 5.3 software after data extract and quality evaluation by Cachrane 5.10. RESULTS：Totally 11 RCTs were enrolled，involving 5 399 patients. Results of Meta-analysis showed，canagliflozin 300 mg/d were superior to 100 mg/d in reducing HbA1c[MD＝0.14，95％CI（0.09，0.19）， P＜0.001]，FPG[MD＝0.40，95％CI（0.20，0.61），P＜0.001] and reduction rate of body mass[MD＝0.69，95％CI（0.42，0.96），P＜ 0.001]，the differences were statistically significant；and there were no significant differences in the incidence of total adverse reactions [RR＝0.97，95％CI（0.94，1.01），P＝0.10]，hypoglycemia [RR＝1.02，95％CI（0.94，1.10），P＝0.67]，urinary tract infection[RR＝ 0.96，95％CI（0.78，1.18），P＝0.69] in 2 groups；There was significantly different of genital mycotic infection in 2 groups[RR＝ 0.84，95％CI（0.70，1.00），P＝0.04]. CONCLUSIONS：Canagliflozin 300 mg/d is better than 100 mg/d in controlling HbA1c，fasting blood glucose and body mass of patients with type 2 diabetes，and the genital mycotic infection should be attentioned.